Vir Biotechnology (NASDAQ:VIR) CAO Brent Sabatini Sells 1,829 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,829 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $7.45, for a total value of $13,626.05. Following the completion of the transaction, the chief accounting officer directly owned 71,043 shares of the company’s stock, valued at $529,270.35. This trade represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Brent Sabatini also recently made the following trade(s):

• On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.79, for a total value of $11,918.70.

Vir Biotechnology Stock Performance

NASDAQ:VIR opened at $9.49 on Wednesday. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -3.00 and a beta of 1.69. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $10.29. The business has a fifty day moving average of $6.80 and a 200-day moving average of $5.99.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The business had revenue of $64.07 million for the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 47.14%. The company’s revenue was up 417.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.76) earnings per share. On average, equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC lifted its holdings in shares of Vir Biotechnology by 2,088.4% during the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after purchasing an additional 256,037 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Vir Biotechnology during the 1st quarter worth about $359,000. Goldman Sachs Group Inc. increased its position in shares of Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after acquiring an additional 225,544 shares in the last quarter. Woodline Partners LP lifted its position in shares of Vir Biotechnology by 245.6% in the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after acquiring an additional 331,701 shares in the last quarter. Finally, Focus Partners Wealth boosted its stake in Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after purchasing an additional 2,566 shares during the period. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Key Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization deal for prostate cancer candidate VIR‑5500 with $335M upfront/near‑term payments and up to $1.37B in milestones plus split U.S. economics — a major de‑risk and commercial validation for the program. Astellas and Vir Biotechnology Announce Global Strategic Collaboration
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported higher‑dose ORR of ~45%), underpinning the asset value and the Astellas deal. Vir Biotechnology Reports Positive Updated Phase 1 Results for VIR-5500
• Positive Sentiment: Quarterly beat and revenue acceleration: Q4 EPS beat estimates and revenue of $64.1M far exceeded expectations (~$19.9M), reflecting strong year‑over‑year growth and better near‑term commercial performance. Vir Biotechnology Q4 Earnings Highlights
• Positive Sentiment: Analyst upgrade/target increases: Needham raised its price target (to $18) and other firms reiterated/upgraded coverage, supporting upside expectations. PT Raised to $18 at Needham
• Neutral Sentiment: Broad media amplification: Extensive coverage (Forbes, Seeking Alpha, MSN) is increasing visibility and trading volume but does not change fundamentals by itself. What’s Happening With VIR Stock?
• Neutral Sentiment: Company disclosures: The earnings call transcript and slide deck provide added pipeline and cash‑position detail for investors to model future milestones and spend. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Proposed public offering: Vir filed to sell additional common stock — proceeds would strengthen the balance sheet but the offering is dilutive and can weigh on near‑term shares. Proposed Public Offering
• Negative Sentiment: Insider selling: Multiple insiders (including the CEO and several senior officers) reported stock sales on Feb. 23 — notable for sentiment and potential supply into the market. Insider Sales Report
• Negative Sentiment: Ongoing losses and wide negative margins: Despite revenue momentum and partnerships, Vir reported a sizable 2025 net loss and negative margins, making long‑term upside contingent on execution and milestone payments. 2025 Financial Results and Corporate Update

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a report on Tuesday, December 30th. Needham & Company LLC boosted their price objective on Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday. Barclays restated an “overweight” rating and issued a $30.00 price objective on shares of Vir Biotechnology in a report on Tuesday. Evercore reaffirmed an “outperform” rating and set a $18.00 target price on shares of Vir Biotechnology in a report on Tuesday. Finally, Morgan Stanley upped their price target on shares of Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $19.88.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.